Elan Stung by Research Report
Elan Stung by Research Report. Tysabri, the multiple sclerosis drug from Biogen Idec (BIIB:Nasdaq) and Elan (ELN:NYSE ADR) , should return to the market but with strict limitations because of safety concerns, according to a survey of doctors conducted by investment research firm Piper Jaffray. The survey revealed that while 92% of … [Read more...] about Elan Stung by Research Report
Colorado widower sues Elan and Biogen
Elan and Biogen Are Being Sued. The widower of a woman who died from a rare brain disease after participating in a clinical trial of Biogen Idec's multiple sclerosis drug Tysabri yesterday sued the Cambridge company and its partner, Elan Pharmaceuticals of Ireland. The wrongful death suit, filed in Middlesex Superior Court by … [Read more...] about Colorado widower sues Elan and Biogen
Biogen, Elan Sued For Allegedly Concealing MS Drug Risks
Risks Of MS Drug Tysabri. A patient is suing Biogen Idec and Elan Corp. PLC, accusing them of concealing risks of their multiple-sclerosis drug Tysabri before withdrawing it from the market. Bloomberg News reported that the patient filed a federal court suit in San Francisco claiming both companies knew the drug could … [Read more...] about Biogen, Elan Sued For Allegedly Concealing MS Drug Risks
Biogen, Elan hit with lawsuit over Tysabri
Lawsuit Against The Maker Of Tysabri. The family of a woman who died in February after participating in a clinical trial of multiple-sclerosis medications has filed a lawsuit against the manufacturers of the drugs. The woman's family has sued Biogen Idec Inc. of Cambridge, Mass., and Elan Pharmaceuticals of San … [Read more...] about Biogen, Elan hit with lawsuit over Tysabri
